Statin Use in Primary Prevention: A Simple Trial-Based Approach Compared With Guideline-Recommended Risk Algorithms for Selection of Eligible Patients

Abstract

The Heart Outcomes Prevention Evaluation (HOPE) 3 study utilised a simple pragmatic risk factor approach to identify individuals that may benefit primary prevention therapy. Comparing outcomes using the Framingham risk score and the 2013 American College of Cardiology / American Heart Association (ACC/AHA) algorithm to outcomes seen in the HOPE-3 trial, showed similar risk reductions in cardiovascular events. However, these risk tools did not identify all participants that were eligible as when using a simple pragmatic approach.